Roche grows against the trend and invests over 700 million euros in Germany

Roche's financial year 2025 in Germany at a glance

• Total sales* increase to around 8.9 billion euros (+4.7 percent).
• Pharmaceuticals Division: The growth of +6.3 percent reflects the high demand for innovative therapies such as Vabysmo, Ocrevus, Evrysdi and Polivy and is an expression of functioning innovation competition as well as an increasing need for care in an ageing society (sales 2025: 2.2 billion euros).
• Diagnostics division: The Diagnostics division developed stably and, at around EUR 909 million (-1%), was almost at the same strong level as the previous year. The blood glucose test strip business recorded an expected decline as a result of the technological shift towards continuous glucose monitoring (CGM, e.g. Accu-Chek SmartGuide). Coagulation self-management also declined due to changes in therapeutic approaches. However, these declines were largely offset by solid growth in the core business.
• Group deliveries: Deliveries from the German sites to the global Roche Group increased to 5.8 billion euros (+5 percent). This underlines the strategic importance of Germany as a technology and production hub within the Group and as an export nation.
• Employees: Roche employed 18,594 people as at December 31, 2025 (+338 compared to 2024), including 643 trainees. According to Prognos AG, a total of around 56,000 jobs in Germany depend directly or indirectly on Roche - each Roche job induces 2.1 jobs.

Roche sends out an investment signal for Germany as a business location

In the 2025 financial year alone, Roche invested around 719 million euros in expanding and maintaining the value of its German sites. The investment volume thus reached a historic high and underlines the company's long-term commitment to Germany as a location for business and innovation. "We have kept our investment promise even under increasingly difficult conditions and pressures," says Dr. Claudia Fleischer, Managing Director of Roche Diagnostics GmbH. "Since 2020, Roche has created over 1,800 new jobs in Germany and invested almost 3.8 billion euros. Our investments are long-term and focus on technology, sites and qualified employees. They are an expression of our clear commitment to Germany - and yet they are not a foregone conclusion. Bureaucracy, overregulation and slow approval procedures are not just challenges. They cause massive additional costs and weaken international competitiveness. This is where politics comes in."

One concrete example of the investments already made in Germany is the Diagnostics Innovation Center in Penzberg, which opened on February 12, 2026 (individual investment: 300 million euros). It stands for precision and high-tech "Made in Germany". Thanks to intelligent networking, fully automated processes and state-of-the-art robotics, the development time for key steps in test development is reduced by 30 percent. "Early diagnostics is the key to effective therapies - for example for cancer or neurodegenerative diseases - and therefore also an important lever for greater efficiency in the healthcare system," emphasizes Daniela Kahlert, Managing Director of Roche Diagnostics Deutschland GmbH.

A key industry that stands for resilience and security of supply

The industrial healthcare sector is one of the few industrial sectors in which Germany continues to occupy a leading international position. The sector is a driver of growth, creates high-quality jobs and makes a significant contribution to financing and stabilizing social security systems. Against the backdrop of an increasingly volatile global environment, the industrial healthcare sector is also gaining strategic importance in the context of national security issues. "Governments around the world have recognized that the importance of our industry goes far beyond health and patient care. It is part of the critical infrastructure and a decisive factor for growth, technological sovereignty and security of supply," emphasizes Dr. Daniel Steiners, CEO of Roche Pharma AG. He adds: "If you want to limit one-sided global dependencies and strengthen resilience, you have to create location conditions that enable value creation, innovation and growth. This also includes an attractive domestic market that supports the sale of innovative products."

Competitiveness in international change

The US administration is currently pushing ahead with far-reaching reforms in several key areas, including, for example, modernizing and increasing the efficiency of the Food and Drug Administration (FDA), reducing bureaucratic hurdles and strengthening domestic pharmaceutical production. These measures are also likely to have consequences for Germany and Europe. "There is much to be said for carefully discussing the new framework conditions and regulations in the USA and their impact on both the business location and supply in Germany together with German politicians and strengthening our own competitiveness," says Dr. Daniel Steiners. There is a particular need for action in the area of industrial policy in Germany. This includes Planning security for long-term investments, accelerated approval processes, consistent digitalization, innovation-friendly market access conditions and appropriate remuneration for innovations.

* Roche's total sales in Germany comprise the sales of the Pharmaceuticals and Diagnostics divisions as well as Group deliveries.